<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791696</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0148</org_study_id>
    <nct_id>NCT04791696</nct_id>
  </id_info>
  <brief_title>Risk Factors for Human Corneal Graft Failure : a Monocentric Retrospective Observational Cohort</brief_title>
  <official_title>Risk Factors for Human Corneal Graft Failure : a Monocentric Retrospective Observational Cohort, Montpellier, South of France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keratoplasty is one of the most common grafts and penetrating keratoplasty is still the&#xD;
      technique most used in the world, ahead of lamellar grafts, and is estimated to represent 70%&#xD;
      of the total.&#xD;
&#xD;
      Graft rejection is still the main cause of failure of this type of surgery, to the extent&#xD;
      that nearly a third of all patients will in some way be affected by rejection in due course.&#xD;
&#xD;
      Numerous risk factors for rejection have been identified, whether related to the donor, the&#xD;
      recipient, or the surgical procedure itself.&#xD;
&#xD;
      In addition, many of the studies performed have used univariate analysis only, and yet there&#xD;
      is a strong case for multivariate analysis, given the wide range of factors that need to be&#xD;
      examined.&#xD;
&#xD;
      This study seeks to analyze the rejection rates and the survival of penetrating keratoplasty&#xD;
      for a group of patients from Montpellier Hospital (France).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>graft rejection</measure>
    <time_frame>1 day</time_frame>
    <description>The main criterion studied is the fact that rejection had occurred, defined by the appearance of a rejection line, whether epithelial or endothelial (Khodadoust line), subepithelial infiltrates, or an anterior chamber inflammatory reaction (Tyndall effect, retro corneal precipitates and Descemet folds) with corneal edema in a previously clear graft. Opaque grafts with no clear period in the 2 weeks after grafting were not considered as rejections, but rather as straightforward graft failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>irreversible graft rejection</measure>
    <time_frame>1 day</time_frame>
    <description>The other criteria studied is irreversible graft rejection, defined as the persistence of a central corneal edema for 3 months despite treatment, and graft failure, defined as a second keratoplasty, or the persistence of a central corneal edema persisting for more than 3 months, whatever the cause (rejection, corneal endothelial cell failure, other).</description>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Corneal Transplant Rejection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutives keratoplasty performed in the ophthalmology department of the CHRU (Centre&#xD;
        Hospitalier RÃ©gional Universitaire) of Montpellier between 15/06/2005 and 18/09/2018, a&#xD;
        period of just over 13 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        -keratoplasty performed in the ophthalmology department of the CHRU of Montpellier between&#xD;
        15/06/2005 and 18/09/2018&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  a non-optical graft (tectonic and analgesic graft)&#xD;
&#xD;
          -  lamellar graft (DALK (Deep Anterior Lamellar Keratoplasty) and DSAEK (Descemet&#xD;
             Stripping Automated Endothelial Keratoplasty))&#xD;
&#xD;
          -  Silica gel re-dried cornea, duplicates (we included each patient only once per eye)&#xD;
&#xD;
          -  medical record missing from the archives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent DAIEN, MD, PhD, HDR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cornea / surgery</keyword>
  <keyword>Corneal Transplantation* / adverse effects</keyword>
  <keyword>Corneal Transplantation* / methods</keyword>
  <keyword>Graft Rejection / prevention &amp; control</keyword>
  <keyword>Humans</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

